Tiffany is a PhD candidate investigating risk factors, phenotypes and outcome measures used to assess chemotherapy-induced peripheral neurotoxicity with a focus on haematological malignancies, at the University of Sydney, Australia. Tiffany has been working in the field of clinical CIPN research for over 6 years, with experience in applying nerve excitability techniques to patients undergoing chemotherapy. In recent years, Tiffany has been awarded a number of grants to investigate axonal degeneration following neurotoxic cancer treatment and to develop better clinical pathways for CIPN screening.